VolitionRX Forecast, price target & analysts
VolitionRX Target price 2025 - Analyst rating & recommendation
VolitionRX Classifications & Recommendation:
VolitionRX Price Target
| Target Price | $2.92 |
| Price | $0.46 |
| Potential |
531.53%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target VolitionRX 2026 .
The average VolitionRX target price is $2.92.
This is
531.53%
register free of charge
$5.00
979.91%
register free of charge
$2.00
331.97%
register free of charge
|
|
| A rating was issued by 5 analysts: 4 Analysts recommend VolitionRX to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the VolitionRX stock has an average upside potential 2026 of
531.53%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.23 | 7.48 |
| 57.69% | 508.09% | |
| EBITDA Margin | -2,091.06% | -205.80% |
| 52.83% | 90.16% | |
| Net Margin | -2,422.03% | -202.36% |
| 60.68% | 91.65% |
5 Analysts have issued a sales forecast VolitionRX 2025 . The average VolitionRX sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast VolitionRX 2025 . The average VolitionRX EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 VolitionRX Analysts have issued a net profit forecast 2025. The average VolitionRX net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.31 | -0.16 |
| 38.00% | 48.39% | |
| P/E | negative | |
| EV/Sales | 6.42 |
4 Analysts have issued a VolitionRX forecast for earnings per share. The average VolitionRX EPS is
This results in the following potential growth metrics and future valuations:
Current VolitionRX Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 12 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
